Therapeutic Drug Monitoring Based on Early Measurements of Serum Teicoplanin Levels in Japanese Patients

Oda, Kazutaka; Kasada, Takashi; Yoshikawa, M; Tanoue, Mitsunori; Yamashita, Takuro; Takeshita, Yusuke

doi:10.1097/ftd.0000000000000002

Cited by 8 publications

(6 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The concentrations of teicoplanin which revealed cell toxicity were much higher than the clinically used concentrations (Tobin et al ., 2010 ; Matthews et al ., 2014 ; Salimi et al ., 2014 ; Oda et al ., 2014 ). It might thus be concluded that teicoplanin appears to be a safe drug.…”

Section: Resultsmentioning

confidence: 99%

Effects of teicoplanin on cell number of cultured cell lines

Kashkolinejad-Koohi

Saadat

2015

Interdisciplinary Toxicology

View full text Add to dashboard Cite

Teicoplanin is a glycopeptide antibiotic with a wide variation in human serum half-life. It is also a valuable alternative of vancomycin. There is however no study on its effect on cultured cells. The aim of the present study was to test the effect of teicoplanin on cultured cell lines CHO, Jurkat E6.1 and MCF-7. The cultured cells were exposed to teicoplanin at final concentrations of 0–11000 μg/ml for 24 hours. To determine cell viability, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) test was performed. At low concentrations of teicoplanin the numbers of cultured cells (due to cell proliferation) were increased in the three cell lines examined. The maximum cell proliferation rates were observed at concentrations of 1000, 400, and 200 μg/ml of teicoplanin for CHO, MCF-7 and Jurkat cell lines, respectively. Cell toxicity was observed at final concentrations over 2000, 6000, and 400 μg/ml of teicoplanin for CHO, MCF-7 and Jurkat cell lines, respectively. A dose-dependent manner of cell toxicity was observed. Our present findings indicated that teicoplanin at clinically used concentrations induced cell proliferation. It should therefore be used cautiously, particularly in children, pregnant women and patients with cancer.

show abstract

Section: Resultsmentioning

confidence: 99%

Effects of teicoplanin on cell number of cultured cell lines

Kashkolinejad-Koohi

Saadat

2015

Interdisciplinary Toxicology

View full text Add to dashboard Cite

show abstract

“…Interestingly, trough concentration before day 7 was less correlated with AUC SS (coefficient of determination = 0.442), indicating that compliance with the target trough concentration range during the first week would not accord with the AUC SS . Oda et al demonstrated that maximum a posteriori dosing based on Bayesian estimation could improve the compliance rate of trough concentration within its target range rather than the maximum a priori dosing 9 . TDM guidelines recommend that sampling for teicoplanin TDM should be performed 4 days after the start of therapy and follow‐up TDM within 7 days in patients who are susceptible to being outside the target range or require a higher target concentration.…”

Section: Discussionmentioning

confidence: 99%

“…A population involving 1000 virtual individuals was generated following two population pharmacokinetic (PopPK) studies. As this study is in accordance with the Japanese population, the most popular PopPK model incorporated in this application was used as the concordant PopPK model (PopPK JP ) 8–10 . Another model was developed in a prospective study with rich samplings and discordance with a Japanese population from Ireland (PopPK nonJP ) 11 .…”

Section: Methodsmentioning

confidence: 99%

“…As this study is in accordance with the Japanese population, the most popular PopPK model incorporated in this application was used as the concordant PopPK model (PopPK JP ). 8 , 9 , 10 Another model was developed in a prospective study with rich samplings and discordance with a Japanese population from Ireland (PopPK nonJP ). 11 These models are presented in Table S1 .…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Model‐informed precision dosing of teicoplanin for the rapid achievement of the target area under the concentration‐time curve: A simulation study

Oda

Yamada²,

Matsumoto

et al. 2023

Clinical Translational Sci

Self Cite

View full text Add to dashboard Cite

Teicoplanin, a glycopeptide antimicrobial, is recommended for therapeutic drug monitoring, but it remains unclear how to target the area under the concentration-time curve (AUC). This simulation study purposed to demonstrate the potential of the Bayesian forecasting approach for the rapid achievement of the target AUC for teicoplanin. We generated concordant and discordant virtual populations against a Japanese population pharmacokinetic model. The predictive performance of the Bayesian posterior AUC in limited sampling on the first day against the reference AUC was evaluated as an acceptable target AUC ratio within the range of 0.8-1.2. In the concordant population, the probability for the maximum a priori or Bayesian posterior AUC on the first day (AUC 0-24 ) was 61.3% or more than 77.0%, respectively. The Bayesian posterior AUC on the second day (AUC 24-48 ) was more than 75.1%. In the discordant population, the probability for the maximum a priori or Bayesian posterior AUC 0-24 was 15.5% or 11.7-80.7%, respectively. The probability for the maximum a priori or Bayesian posterior AUC 24-48 was 23.4%, 30.2-82.1%. The AUC at steady-state (AUC SS ) was correlated with trough concentration at steady-state, with a coefficient of determination of 0.930; the coefficients on days 7 and 4 were 0.442 and 0.125, respectively. In conclusion, this study demonstrated that early sampling could improve the probability of AUC 0-24 and AUC 24-48 but did not adequately predict AUC SS .Further studies are necessary to apply early sampling-based model-informed precision dosing in the clinical settings.

show abstract

“…However, the prediction error of drug concentration based on the population mean method could have been observed. 8) Similar to TEIC, vancomycin (VCM) is a renally eliminated drug, which is an important pharmacokinetic parameter that must be considered in calculating the dose of VCM or TEIC to achieve therapeutic concentration range.…”

Section: Introductionmentioning

confidence: 99%

Improvement of Predictivity of Teicoplanin Serum Trough Concentrations at Steady State Calculated by Vancomycin Pharmacokinetic Parameter

Kobayashi

Otomo²,

Shiba³

et al. 2016

YAKUGAKU ZASSHI

View full text Add to dashboard Cite

According to a recent study and meta-analysis, trough levels of ＞10 mg/mL teicoplanin (TEIC) may be acceptable for the treatment of uncomplicated infection, but no method of TEIC personalized medicine has been established. Vancomycin (VCM) and TEIC are glycopeptide antibiotic agents eŠective against methicillin-resistance Staphyloccocus aureus. This study aimed to establish TEIC personalized medicine at a steady state calculated by VCM pharmacokinetic parameters. Bayesian forecasting and population mean methods were employed to estimate individual total VCM clearance (CL) using existing population pharmacokinetics (PPK) parameter, and the diŠerences between the CL calculated by these two methods were deˆned as DCL. Serum drug concentration data for patients treated with TEIC were collected at a steady state concentration (＞96 h post infusion). There was a signiˆcant relationship between the prediction error of TEIC trough level and DCL. The relation between DCL and TEIC trough concentration at steady state was used to develop the following equation to determine the maintenance dose: TEIC (mg/mL)＝1.1119X-6.124DCL＋3.9164 (X is deˆned as TEIC trough concentration calculated from the PPK parameter). The results of this study indicated that it is possible to improve the prediction error of TEIC trough concentration at a steady state for patients who have received VCM therapy.

show abstract

Therapeutic Drug Monitoring Based on Early Measurements of Serum Teicoplanin Levels in Japanese Patients

Abstract: A simulation based on the Bayesian method using C(2-3) of TEIC is acceptable in clinical settings.

Cited by 8 publications

References 13 publications

Effects of teicoplanin on cell number of cultured cell lines

Effects of teicoplanin on cell number of cultured cell lines

Model‐informed precision dosing of teicoplanin for the rapid achievement of the target area under the concentration‐time curve: A simulation study

Improvement of Predictivity of Teicoplanin Serum Trough Concentrations at Steady State Calculated by Vancomycin Pharmacokinetic Parameter

Contact Info

Product

Resources

About